Company news

Aquestive Therapeutics, Inc. (NASDAQ:AQST) news

Aquestive Therapeutics, Inc. news releases on 6ix. Latest, Sep 29, 2026: Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Aquestive Therapeutics, Inc. (NASDAQ:AQST) news

Press releases & updates

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Aquestive Therapeutics Announces Leadership Expansion to Support Growth

Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler

Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences